The British Society for Haematology has released a new updated guideline that offers practical guidance for the management of specific situations and complications of polycythemia vera and outlines management of the diverse types of secondary erythrocytosis.
The British Society for Haematology has released a new updated guideline1 that offers practical guidance for the management of specific situations and complications of polycythemia vera (PV) and outlines management of the diverse types of secondary erythrocytosis. The guideline was compiled using a process that evaluated levels of evidence and strength of recommendations in the medical literature from 1215 articles that were generated between 2005 and 2017.
Thrombosis in PV. Thrombotic events are the major cause of morbidity and mortality in PV, and their prevention is the main objective of treatment. Additionally, these events have a signiifcant economic impact. Approximately a third of patients present with a thrombotic event, and younger patients diagnosed with PV have an increased risk of early death from cardiovascular disease than the general population, accounting for 45% of all deaths in PV. Arterial thrombosis involving large arteries and peripheral vascular disease are more common than venous thromboembolism in PV.
The guideline recommends the following for acute thrombotic events:
Unusual sites of venous thrombosis are more common in patients with myeloproliferative neoplasms, including splanchnic vein thrombosis (SVT) and cerebral vein thrombosis. The splanchnic circulation is particularly vulnerable in patients with JAK2 and V617F mutations.
Hemorrhage. While less frequent and a less severe complication of PV than thrombosis, hemorrhage affects the skin, mucous membranes, and the gastrointestinal tract.
Patients with PV undergoing surgery are, paradoxically, at high-risk of both hemorrhage and thrombosis. It is therefore important that these patients are assessed preoperatively and abnormal counts are optimized, balancing the acute need for surgical procedure against the risk of bleeding and thrombosis. Recommendations for perioperative management include:
Pruritis. A common phenomenon in PV, pruritis occurs in up to 85% of patients and can be challenging to manage. It can have a significant negative impact on quality of life, affecting sleep and participation in social activities. Intensity varies but can be severe, causing emotional depression, anxiety, and even suicide ideation. Pruritis can persist even after blood counts are normalized. The guideline discusses medications and other therapies and cooperative consultation with dermatologists in refractory cases.
Pregnancy. PV is uncommon in females of reproductive age, but the guidance makes recommendations for pregnancy management in PV patients, which should be done in close cooperation between obstetricians and hematologists.
Secondary erythrocytosis. The guideline addresses secondary erythrocytosis, both idiopathic (IE) and congenital. There are no clinical studies on the use of aspirin or venesection in IE and thus evidence-based recommendations cannot be made. Thrombotic risk factors should be evaluated in each individual IE case. Genetic testing is recommended. Congenital erythrocytosis encompasses a wide range of defects and is rare, with little hard data available to help advise on its management. Low-dose aspirin and venesection should be considered.
Finally, the guidelines discuss recommendations for erythrocytosis in hypoxic pulmonary disease and posttransplant erythrocytosis.
Reference
1. McMullin MFF, Mead AJ, Ali S, et al; British Society for Haematology Guideline. A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis. A British Society for Haematology Guideline [published online November 13, 2018]. Br J Haematol. doi: 10.1111/bjh.15647.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More